The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment

Oncology Reports

Volumn 27, Issue 3, 2012, Pages 741-747

  Skírnisdóttir, Ingirídur ^a   Seidal, T ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HALMSTAD HOSPITAL   (Sweden)

Author keywords

Bax; Ovarian cancer; p53; Prognostic markers; PUMA

Indexed keywords

CARBOPLATIN; PACLITAXEL; PROTEIN BAX; PROTEIN P53; PUMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SURVIVAL PREDICTION; TISSUE MICROARRAY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BRIDGED COMPOUNDS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856273810     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1578     Document Type: Article

References (32)

1. Chan JK, Tian C, Teoh D, et al: Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 16: 307-311, 2010.
2. Heintz AP, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. Int J Gynaecol Obstet 83: 135-166, 2003. (Pubitemid 39658498)
3. Ozols RF, Dembo AJ and Robboy S: Epithelial ovarian cancer. In: Principles and Practice of Gynecologic Oncology. Hoskins WJPC and Young RC (eds). Lippincott, Philadephia, pp731-781, 1992.
4. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007. (Pubitemid 46148091)
5. Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB and Swenerton KD: Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol 116: 50-56, 2010.
6. Schuyer M, van der Burg M, Henzen-Logmans SC, et al: Reduced expression is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 85: 1359-1367, 2001. (Pubitemid 33081933)
7. Nam EJ and Kim YT: Alteration of cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol Cancer 18: 1169-1182, 2008.
8. Foster I: Cancer: a cell cycle defect. Radiography 14: 144-149, 2008.
9. Palmer JE, Sant Cassia LJ, Irwin CJ, et al: P53 and bcl-2 assessment in serous carcinoma. J Gynecol Cancer 18: 241-248, 2008. (Pubitemid 351365201)
10. Lee DH, Kim C, Zhang L, et al: Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochem Pharmacol 75: 2020-2033, 2008.
11. Liu YY, Patwardhan GA, Bhinge K, Gupta V, Gu X and Jarwinski M: Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res 71: 2276-2285, 2011.
12. Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005. (Pubitemid 40638098)
13. Yamaguchi H, Chen J, Bhalla K and Wang HG: Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and independent pathways. J Biol Chem 279: 39431-39437, 2004. (Pubitemid 39258208)
14. de la Torre FJ, García A, Gil-Moreno A, et al: Apoptosis in epithelial ovarian tumours. Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax). Eur J Obstet Gynecol Reprod Biol 130: 121-128, 2007. (Pubitemid 44918191)
15. Skirnisdottir I, Sorbe B and Seidal T: A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer 14: 259-270, 2004. (Pubitemid 38533897)
16. Skirnisdottir I, Sorbe B and Seidal T: p53, bcl-2, bax; their relationship and effect on prognosis in early stage ovarian carcinoma. Int J Gynecol Cancer 141: 241-248, 2001.
17. Sinicrope FA, Rego RL, Okumura K, et al: Prognostic impact of Bim, Puma and Noxa expression in human colon carcinomas. Clin Cancer Res 14: 5810-5818, 2008.
18. Skirnisdottir I, Sorbe B, Lindborg K and Seidal T: Prognostic impact of p53, p27 and C-MYC on clinico-pathological features and outcome in early stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer 21: 236-244, 2011.
19. Skirnisdottir I and Seidal T: Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer (EOC). Int J Gynecol Cancer 21: 1024-1031, 2011.
20. Trimbos JB, Vergote I, Bolis G, et al: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 18: 113-125, 2003. (Pubitemid 36193260)
21. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998. (Pubitemid 28331029)
22. Seidal T, Balaton AJ and Battifora H: Interpretation and quantification of immunostains. Am J Surg Pathol 25: 1204-1207, 2001. (Pubitemid 32777722)
23. Darcy KM, Brady WE, McBroom JW, et al: Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelian ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol 111: 478-495, 2008.
24. Lassus H, Leminen A, Lundin J, Lehtovirta P and Butzow R: Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 91: 504-512, 2003. (Pubitemid 38388142)
25. Skirnisdottir I, Seidal T, Gerdin E and Sorbe B: The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 12: 265-276, 2002. (Pubitemid 34787554)
26. de la Torre J, Gil-Moreno A, García A, et al: Expression of DNA damage checkpoint protein Hus 1 in epithelial ovarian tumors correlates wit prognostic markers. Int J Gynecol Patholog 27: 24-32, 2008. (Pubitemid 351627968)
27. Chan JK, Tian C, Monk BJ, et al: Prognostic factors for high-risk early-stage epithelial ovarian cancer. Cancer 112: 2202-2210, 2008.
28. de Graeff P, Crinjs APG, de Jong S, et al: Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelian ovarian cancer: a meta-analysis. Br J Cancer 101: 149-159, 2009.
29. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
30. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002. (Pubitemid 34161136)
31. Fei P and El-Dairy WS: P53 and radiation responses. Oncogene 22: 5774-5783, 2003. (Pubitemid 37176699)
32. Wang P, Yu J and Zhang L: The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage. Proc Natl Acad Sci USA 104: 4054-4059, 2007. (Pubitemid 47181577)